Vitamin C supplementation had no side effect in non-cancer, but had anticancer properties in ovarian cancer cells
Abstract
Abstract. Vitamin C (Vit C) has been widely used in the treatment and prevention of cancer. Nevertheless, the clinical results are still inconclusive. Using non-cancer (HOSEpiC) and cancer OVCAR-3 cells cultured in basal medium or in ovarian cancer-associated fibroblast (CAF)-supplemented medium, we estimated the dose-dependent effect of Vit C on sodium–ascorbate co-transporters (SVCT1, SVCT2) and glucose transporter (GLUT1) protein expression. Additionally, the action of Vit C on cell proliferation (alamarBlue), membrane permeability (LDH assay), caspase3 activity, the selected cell cycle and apoptosis pathway, poly(ADP-ribose) polymerase-1 (PARP) protein expression, and reactive oxygen species (ROS) activity was determined. We showed different effects of Vit C on the expression of the co-transporter in non-cancer and cancer cells. In non-cancer cells, Vit C, at a pharmacological concentration, increased SVCT2 and decreased GLUT1, while the opposite effect was noted in cancer cells. In cancer cells, Vit C, in a pharmacological dose, decreased cell proliferation through an inhibitory effect on cyclin-dependent kinase 2 (CDK2) (4.4-fold; p < 0.01), mainly due to the stimulatory effect on the expression of cyclin-dependent kinase (CDK) inhibitors, such as p21 and p53 (3.2- and 2.8-fold, respectively; p < 0.001), but not caspase pathway. The tumour microenvironment caused inefficiency of the lower doses of Vit C in ovarian cancer cells. At a pharmacological dose of 1 mM, Vit C decreased PARP expression (1.5-fold; p < 0.05). We suggest that it’s nontoxic effects on non-cancer cells may be an indicator of its prophylactic use, while in a pharmacological dose Vit C should be considered a possible adjunctive drug in ovarian cancer. However, it is necessary to consider the effect of the CAF.
References
1 , Ovarian cancer development and metastasis. Am J Pathol. 2010;177:1053–64.
2 , Getting to Know Ovarian Cancer Ascites: Opportunities for Targeted Therapy-Based Translational Research. Front Oncol. 2013;3:256.
3 , Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol. 2007;18(5):945–9.
4 , Ovarian carcinoma and serous effusions. Changing views regarding tumor progression and review of current literature. Anal Cell Pathol. 2001;23:107–28.
5 , Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med. 2004;140:533–537.
6 , Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. PNAS. 2005;102:13604–13609.
7 , H2O2-mediated cytotoxicity of pharmacologic ascorbate concentrations to neuroblastoma cells: potential role of lactate and ferritin. Cell Physiol Biochem. 2010;25:767–774.
8 , The effect of intravenous vitamin C on cancer and chemotherapy-related fatigue and quality of life. Front Oncol. 2014;4:283.
9 , High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial. PLoS One. 2015;10:e0120228.
10 , High-Dose Parenteral Ascorbate Enhanced Chemosensitivity of Ovarian Cancer and Reduced Toxicity of Chemotherapy. Science Transl Md. 2014;6:222ra18.
11 , Vitamin C augments chemotherapeutic response of cervical carcinoma HeLa cells by stabilizing P53. Biochem Biophys Res Commun. 2001;282:409–415.
12 , Potentiation of the effect of paclitaxel and carboplatin by antioxidant mixture on human lung cancer h520 cells. J Am Coll Nutr. 2002;21:416–21.
13 , Vitamin C effect on mitoxantrone-induced cytotoxicity in human breast cancer cell lines. PLoS One. 2014;9(12):e115287.
14 , Vitamins C and K3 sensitize human urothelial tumors to gemcitabine. J Urol. 2006;176:1642–7.
15 , Treatment of pancreatic cancer with pharmacological ascorbate. Curr Pharm Biotechnol. 2015;16:75–70.
16 , The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. J Am Coll Nutr. 2003;22:118–23.
17 , High-Dose Vitamin C Helps Prevent Recurrence of Stage IV Ovarian Cancer: A Case Report. J Orthomol Med. 2018;33:1–5.
18 , A peek into cancer-associated fibroblasts: origins, functions and translational impact. Dis Model Mech. 2018;11(4).
19 , Role of tumor microenvironment in ovarian cancer pathobiology. Oncotarget. 2018;9(32):22832–49.
20 , Cancer-associated fibroblasts from hepatocellular carcinoma promote malignant cell proliferation by HGF secretion. PLoS One. 2013;8(5):e63243.
21 Fibroblasts in omentum activated by tumor cells promote ovarian cancer growth, adhesion and invasiveness. Carcinogenesis. 2012;33(1):20–9.
22 , Cancer associated fibroblasts express pro-inflammatory factors in human breast and ovarian tumors. Biochem Biophys Res Commun. 2013;437(3):397–402.
23 , Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. Front Oncol. 2014;4:62.
24 , Dehydroascorbic acid transport by GLUT4 in Xenopus oocytes and isolated rat adipocytes. J Biol Chem. 2000;275(36):28246–53.
25 , A family of mammalian Na+-dependent L-ascorbic acid transporters. Nature. 1999;399(6731):70–5.
26 , Pharmacokinetic and anti-cancer properties of high dose ascorbate in solid tumours of ascorbate-dependent mice. Free Radic Biol Med. 2016;99:451–462.
27 , Decreased expression of the Vit C transporter SVCT1 by ascorbic acid in a human intestinal epithelial cell line. Br J Nutr. 2002;87(2):97–100.
28 , New developments and novel therapeutic perspectives for Vit C. J Nutr. 2007;137(10):2171–84.
29 , Vit C transport systems of mammalian cells. Mol Membr Biol. 2001;18(1):87–95.
30 , A human sodium-dependent Vit C transporter 2 isoform acts as a dominant-negative inhibitor of ascorbic acid transport. Mol Cell Biol. 2004;24(8):3150–6. Erratum in: Mol Cell Biol. 2004;24(14):6537.
31 Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A. 2008;105(32):11105–9.
32 , Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res. 2009;69(16):6565–72.
33 , An important role for CDK2 in G1 to S checkpoint activation and DNA damage response in human embryonic stem cells. Stem cells. 2011;29(4):651–9.
34 , Ascorbate induces apoptosis in melanoma cells by suppressing Clusterin expression. Sci Rep. 2017;7(1):3671.
35 , Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. Oncogene. 1994;9(6):1791–8.
36 , At the gates of death. Cancer Cell. 2006;9:328–30.
37 , The role of p53 in chemosensitivity and radiosensitivity. Oncogene. 2003;22(47):7486–95.
38 , Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene. 1994;9(8):2261–8.
39 , Hongging W. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells. Biosci Rep. 2017;37(2).
40 , GRP78/BiP inhibits endoplasmic reticulum BIK and protect human breast cancer cells against estrogen starvation-induced apoptosis. Cancer Research. 2007;67:3734–40.
41 , Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics. Antioxid. Redox Signal. 2013;19:2141–2156.
42 Protective effect of Vit C on oxidative stress: a randomized controlled trial. Int J Vitam Nutr Res. 2008;78(3):121–8.
43 , Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA. 2007;104:8749–54.
44 , The DNA damage response and cancer therapy. Nature. 2012;481:287–94.
45 , Nonhomologous end joining drives poly(ADPribose) polymerase (PARP) inhibitor lethality in homologous recombinationdeficient cells. Proc Natl Acad Sci USA. 2011;108(8):3406–11.
46 , Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-Ribose) polymerase. Nature. 2005;434:913–7.
47 , Cancer-associated fibroblast: naughty neighbors that drive ovarian cancer progression. Cancers. 2018;10(11).
48 , Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer. 2012;12:323–34.
